Moreover, CHD1 is involved in cancer progression via regulation of NF-κB target genes in PTEN-deficient prostate cancer22, and CHD1 alters androgen receptor binding sites in CHD1-deleted androgen receptor-positive prostate cancer cells59 and abrogates anti-androgenic effects by causing induction of transcription factors such as the glucocorticoid receptor60. This evidence concerns the gene NFKB1 and Familial prostate cancer.